1 hour ago
1
Eoneren/E+ via Getty Images
- Sanofi (NASDAQ:SNY) (OTCPK:SNYNF) (GCVRZ) announced that the European Medicines Agency (EMA) has given orphan designation to its experimental drug, rilzabrutinib, for the treatment of IgG4-related disease.
- Currently, rilzabrutinib is undergoing regulatory review in the United States, European Union, and China for its potential
English (US) ·